Combined with the right sequencing technology, Cao's chip could allow doctors to tailor medical treatment to a patient's unique genetic profile, map new genes linked to specific diseases, and quickly identify new viruses and outbreaks.

Han Cao founded BioNanomatrix in 2003 as a spin out of the Princeton University laboratory where he was working on a multi-million dollar project funded by the U.S. Defense Advanced Research Projects Agency (DARPA).

Dr. Cao is a co-inventor of the company’s core single-molecule nanoscale whole genome analysis technology. His diverse scientific experience includes molecular biology, microarray and genomics technology development, as well as micro and nanofluidics design and fabrication.

Dr. Cao leads multiple federal government funded projects at BioNanomatrix and is a member of the study section of the Innovative Molecular Analysis Technologies (IMAT) Program of the National Cancer Institute.

Image: Princeton University

Also read: World's top 10 patent leaders

Back

Next